Cargando…
Risk of COPD Exacerbations Associated with Statins versus Fibrates: A New User, Active Comparison, and High-Dimensional Propensity Score Matched Cohort Study
BACKGROUND: Several observational studies have found that statins may materially decrease the risk of chronic obstructive pulmonary disease (COPD) exacerbations. However, most of these studies used a prevalent user, non-user comparison approach, which may lead to overestimation of the clinical benef...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491865/ https://www.ncbi.nlm.nih.gov/pubmed/34621122 http://dx.doi.org/10.2147/COPD.S323391 |
_version_ | 1784578814067605504 |
---|---|
author | Sun, Shu-Hui Chang, Chia-Hsuin Zhan, Zhe-Wei Chang, Wen-Hsuan Chen, Yu-An Dong, Yaa-Hui |
author_facet | Sun, Shu-Hui Chang, Chia-Hsuin Zhan, Zhe-Wei Chang, Wen-Hsuan Chen, Yu-An Dong, Yaa-Hui |
author_sort | Sun, Shu-Hui |
collection | PubMed |
description | BACKGROUND: Several observational studies have found that statins may materially decrease the risk of chronic obstructive pulmonary disease (COPD) exacerbations. However, most of these studies used a prevalent user, non-user comparison approach, which may lead to overestimation of the clinical benefits of statins. We aimed to explore the risk of COPD exacerbations associated with statins with a new user, active comparison approach to address potential methodological concerns. We selected fibrates, another class of lipid-lowering agents, as the reference group because no evidence suggests that fibrates have an effect on COPD exacerbations. METHODS: We identified patients with COPD who initiated statins or fibrates from a nationwide Taiwanese database. Patients were followed from cohort entry to the earliest of the following: hospitalization for COPD exacerbations, death, end of the data, or 180 days after cohort entry. Stratified Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of COPD exacerbations comparing statins with fibrates after variable-ratio propensity score (PS) matching and high-dimensional PS (hd-PS) matching, respectively. RESULTS: We identified a total of 134,909 eligible patients (110,726 initiated statins; 24,183 initiated fibrates); 1979 experienced COPD exacerbations during follow-up. The HRs were 1.10 (95% CI, 0.96 to 1.26) after PS matching and 1.08 (95% CI, 0.94 to 1.24) after hd-PS matching. The results did not differ materially by type of statins and patient characteristic and did not change with longer follow-up durations. CONCLUSION: This large-scale, population-based cohort study did not show that use of statins was associated with a reduced risk of acute exacerbations in patients with COPD using state-of-the-art pharmacoepidemiologic approaches. The findings emphasize the importance of applying appropriate methodology in exploring statin effectiveness in real-world settings. |
format | Online Article Text |
id | pubmed-8491865 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-84918652021-10-06 Risk of COPD Exacerbations Associated with Statins versus Fibrates: A New User, Active Comparison, and High-Dimensional Propensity Score Matched Cohort Study Sun, Shu-Hui Chang, Chia-Hsuin Zhan, Zhe-Wei Chang, Wen-Hsuan Chen, Yu-An Dong, Yaa-Hui Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: Several observational studies have found that statins may materially decrease the risk of chronic obstructive pulmonary disease (COPD) exacerbations. However, most of these studies used a prevalent user, non-user comparison approach, which may lead to overestimation of the clinical benefits of statins. We aimed to explore the risk of COPD exacerbations associated with statins with a new user, active comparison approach to address potential methodological concerns. We selected fibrates, another class of lipid-lowering agents, as the reference group because no evidence suggests that fibrates have an effect on COPD exacerbations. METHODS: We identified patients with COPD who initiated statins or fibrates from a nationwide Taiwanese database. Patients were followed from cohort entry to the earliest of the following: hospitalization for COPD exacerbations, death, end of the data, or 180 days after cohort entry. Stratified Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of COPD exacerbations comparing statins with fibrates after variable-ratio propensity score (PS) matching and high-dimensional PS (hd-PS) matching, respectively. RESULTS: We identified a total of 134,909 eligible patients (110,726 initiated statins; 24,183 initiated fibrates); 1979 experienced COPD exacerbations during follow-up. The HRs were 1.10 (95% CI, 0.96 to 1.26) after PS matching and 1.08 (95% CI, 0.94 to 1.24) after hd-PS matching. The results did not differ materially by type of statins and patient characteristic and did not change with longer follow-up durations. CONCLUSION: This large-scale, population-based cohort study did not show that use of statins was associated with a reduced risk of acute exacerbations in patients with COPD using state-of-the-art pharmacoepidemiologic approaches. The findings emphasize the importance of applying appropriate methodology in exploring statin effectiveness in real-world settings. Dove 2021-10-01 /pmc/articles/PMC8491865/ /pubmed/34621122 http://dx.doi.org/10.2147/COPD.S323391 Text en © 2021 Sun et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Sun, Shu-Hui Chang, Chia-Hsuin Zhan, Zhe-Wei Chang, Wen-Hsuan Chen, Yu-An Dong, Yaa-Hui Risk of COPD Exacerbations Associated with Statins versus Fibrates: A New User, Active Comparison, and High-Dimensional Propensity Score Matched Cohort Study |
title | Risk of COPD Exacerbations Associated with Statins versus Fibrates: A New User, Active Comparison, and High-Dimensional Propensity Score Matched Cohort Study |
title_full | Risk of COPD Exacerbations Associated with Statins versus Fibrates: A New User, Active Comparison, and High-Dimensional Propensity Score Matched Cohort Study |
title_fullStr | Risk of COPD Exacerbations Associated with Statins versus Fibrates: A New User, Active Comparison, and High-Dimensional Propensity Score Matched Cohort Study |
title_full_unstemmed | Risk of COPD Exacerbations Associated with Statins versus Fibrates: A New User, Active Comparison, and High-Dimensional Propensity Score Matched Cohort Study |
title_short | Risk of COPD Exacerbations Associated with Statins versus Fibrates: A New User, Active Comparison, and High-Dimensional Propensity Score Matched Cohort Study |
title_sort | risk of copd exacerbations associated with statins versus fibrates: a new user, active comparison, and high-dimensional propensity score matched cohort study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491865/ https://www.ncbi.nlm.nih.gov/pubmed/34621122 http://dx.doi.org/10.2147/COPD.S323391 |
work_keys_str_mv | AT sunshuhui riskofcopdexacerbationsassociatedwithstatinsversusfibratesanewuseractivecomparisonandhighdimensionalpropensityscorematchedcohortstudy AT changchiahsuin riskofcopdexacerbationsassociatedwithstatinsversusfibratesanewuseractivecomparisonandhighdimensionalpropensityscorematchedcohortstudy AT zhanzhewei riskofcopdexacerbationsassociatedwithstatinsversusfibratesanewuseractivecomparisonandhighdimensionalpropensityscorematchedcohortstudy AT changwenhsuan riskofcopdexacerbationsassociatedwithstatinsversusfibratesanewuseractivecomparisonandhighdimensionalpropensityscorematchedcohortstudy AT chenyuan riskofcopdexacerbationsassociatedwithstatinsversusfibratesanewuseractivecomparisonandhighdimensionalpropensityscorematchedcohortstudy AT dongyaahui riskofcopdexacerbationsassociatedwithstatinsversusfibratesanewuseractivecomparisonandhighdimensionalpropensityscorematchedcohortstudy |